Market Trends of DNA Repair Drugs Industry
Olaparib Segment is Expected to Hold a Significant Market Share in the DNA Repair Drugs Market Over Forecast Period
- Olaparib is a base-excision repair (BER) enzyme inhibitor that prevents poly-ADP ribose polymerase (PARP), which is involved in the repair of DNA damage caused by oxidative stress. Olaparib is sold under the brand name Lynparza. The advantages offered by Lynparza, such as it demonstrates a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS), reduced risk of cancer recurrences, second cancers or death, and high progression-free-survival rate, over the other DNA repair drugs (rucaparib, niraparib, and others) raises its adoption for the cancer treatment. This is anticipated to fuel the segment's growth over the forecast period.
- According to an article published in Expert Opinion on Pharmacotherapy in April 2021, it has been observed that Olaparib is approved following the administration of at least one line of new hormone therapy and does not require the prior taxane drug to have failed. It can be used for homologous recombination repair (HRR) mutations beyond breast cancer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2). This shows that olaparib can be used more frequently than other drugs, such as rucaparib, for patients with metastatic castration-resistant prostate cancer. This is expected to increase its adoption during prostate cancer treatment, which in turn is anticipated to fuel the segment growth over the forecast period.
- Furthermore, the rising product approvals raise the availability of effective DNA repair drugs in the market, which is also contributing to market growth. For instance, in March 2022, AstraZeneca and MSD's Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Therefore, owing to the factors such as rising product approvals and increasing adoption of olaparib due to its several advantages over other drugs, the studied segment is expected to grow over the forecast period.
Understand The Key Trends Shaping This Market
Download Sample
North America is Expected to Hold Significant Market Share Over the Forecast Period
- North America is expected to witness significant growth in the DNA repair drugs market over the forecast period owing to the factors such as the increasing focus on research and development, the growing number of investments in DNA repair research as well as the growing burden of cancer in the region.
- The increasing incidence and prevalence of various cancers among the population raise the demand for DNA repair drugs which in turn is anticipated to fuel the market growth. For instance, according to 2023 statistics published by ACS, about 1,958,310 new cancer cases (1,010,310 cases in males and 948,000 in females) are expected to be diagnosed in the United States in 2023 as compared to 1,918,030 cases in 2022.
- Additionally, as per 2022 statistics published by the Canada Cancer Society, an estimated 3,000 Canadian women were diagnosed with ovarian cancer in 2022. As per the same source, breast cancer is the most prevalent malignancy and the second-leading cause of cancer-related death in Canadian women. About 28,600 Canadian women were expected to be diagnosed with breast cancer in 2022, which represents 25% of all new cancer cases in women in 2022. Thus, the expected high number of cancer cases among the population is expected to increase the demand for effective treatment options, which in turn is anticipated to propel the market growth.
- Furthermore, the rising company activities in developing cancer drugs are also contributing to the market growth. For instance, in December 2022, Pfizer reported pre-approval single-patient expanded access (compassionate use) of talazoparib for the treatment of patients with metastatic castration-resistant prostate cancer.
- Also, in October 2022, Pfizer reported positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide) plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. Therefore, owing to the factors such as the high burden of cancer and growing company activities, the studied market is expected to grow over the forecast period.
Get Analysis on Important Geographic Markets
Download Sample
